Lateral Flow Immunoassay for Functional C1-INH Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for measuring functional C1-esterase inhibitor (C1-INH) levels in hereditary angioedema (HAE) patients are limited by false positives, low negative predictive value, and lack of rapidness and cost-effectiveness.
Innovation Solution
A lateral flow immunoassay (LFA) device and method for detecting and quantifying functional C1-INH, utilizing a conjugate pad with specific agents and a membrane with capture agents, allowing for rapid and cost-effective qualitative and quantitative analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If chromogenic assay is used to measure C1-INH functional level, then the assay is more sensitive, but it produces false positives more frequently
Solution Approach 1:
The patent combines two different detection approaches (chromogenic detection and turbidimetric detection) into a single assay system. The chromogenic substrate provides sensitive detection while the turbidimetric measurement of C1 complex formation validates functional activity, thereby reducing false positives while maintaining sensitivity.
Solution Approach 2:
The patent introduces C1 complex formation as an intermediary step between the C1-INH measurement and the final detection. By measuring both the chromogenic substrate conversion and the turbidimetric C1 complex formation, the assay uses this intermediate complex as a validator to confirm true positive results and eliminate false positives.
2Reliability
If complex ELISA method is used to measure C1-INH functional level, then false positives are reduced, but the negative predictive value decreases to 62%
Solution Approach 1:
The patent merges the advantages of ELISA (reduced false positives) with the functional assessment capability of chromogenic assays. By combining multiple detection modalities including chromogenic substrate conversion, turbidimetric C1 complex formation, and quantitative analysis, the assay achieves both high reliability and high negative predictive value.
3Measurement precision
If current C1-INH assays are used, then functional C1-INH levels can be measured, but the assays are not rapid and cost-effective
Solution Approach 1:
The patent employs a self-contained microtiter plate assay system where all reagents, substrates, and detection components are integrated into the plate format. The assay performs multiple measurements (chromogenic conversion, turbidimetric C1 complex formation) automatically through sequential additions and readings, eliminating the need for separate processing steps and reducing both time and cost while maintaining functional measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LFA device provides a rapid, sensitive, and cost-effective means to detect and quantify functional C1-INH levels, improving diagnostic accuracy and ease of use, particularly in physician's office labs, thereby expanding screening and monitoring capabilities for HAE.
Implementation Method 1
a lateral flow immunoassay (LFA)
Implementation Method 2
a first agent and a second agent are immobilized, respectively... on which a third agent is immobilized... fC1-INH binding agent... C1-INH binding agent... capture agent
Data Source
AI summary
A device for detecting and/or quantifying functional C1-esterase inhibitor (fC1-INH), the device comprising: (i) a conjugate pad comprising a first zone and a second zone, on which a first agent and a second agent are immobilized, respectively, and (ii) a membrane, which is in communication with the conjugate pad, wherein the membrane comprises a third zone, on which a third agent is immobilized. The conjugate pad may further comprise a fourth zone for placing a biological sample, which flows through the device in the order of the first zone, the second zone, and the third zone.